Professor Joanne Edwards

Professor of Translational Cancer Pathology (Therapeutic Science Research)
Director of Education (School of Cancer Sciences)

telephone: 01413307244
email: Joanne.Edwards@glasgow.ac.uk
pronouns: She/her/hers

Wolfson Wohl Building, Garscube Estate, Switchback Road, Glasgow, G61 1qh

Biography

Joanne Edwards is Professor of Translational Cancer Pathology and Principal Investigator at the School of Cancer Sciences, University of Glasgow. She is also Director of Education for the School of Cancer Sciences, Lead of the Colorectal Cancer Theme for the Cancer Research UK Scotland Centre, Director of the Glasgow Tissue Research Facility and Director of the Integrated Technologies for Improved Polyp Surveillance (INCISE) project.

She received her PhD from the University of St Andrews before moving to Glasgow in 1997. With over 20 years of experience in cancer biomarker research and therapeutics, her research focuses on colorectal and breast cancer. She has an H-index of 70, has published more than 200 scientific papers, with over 17,000 citations, and has established an international network of collaborators.

She has developed unique patient tissue cohorts with extensive linked clinical data across a breadth of solid tumours, gaining an international reputation for her expertise in developing biomarkers for personalised patient care. Notably, despite being a non-clinical researcher, her work has led to her election as a Fellow of the Royal College of Pathologists.

Joanne leads a multidisciplinary team of scientists and surgeons and has supervised over 20 PhD students. As a mentor, she strives to support the next generation of cancer researchers and inspire them through their educational careers as PhD students and post-doctoral scientists.

Research interests

Joanne's work aims to better understand the determinants of short- and long-term outcomes in patients with colorectal and breast cancer, particularly the relationship between local and systemic inflammatory responses, the tumour microenvironment and cell signalling, with the goal of integrating this knowledge into routine clinical management.

Central to this work is the team’s large collection of tissue microarrays, which allow for the identification of clinically relevant prognostic and predictive biomarkers. In more recent years, her research has expanded to include AI computational pathology, genomics, transcriptomics, spatial biology and the development of human models such as tissue explants, patient-derived organoids and patient-derived co-culture models.

The overarching aim of the team's research is to develop novel treatment strategies to establish a personalised medicine approach for colorectal and breast cancer.

Research groups

Cancer Evolution in Time & Space
Immunology & Cancer

Publications

List by: Type | Date

Jump to: 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 1999

Number of items: 219.

2024

Galbraith, N. J. et al. (2024) TAK1 expression is associated with increased PD-L1 and decreased cancer-specific survival in microsatellite-stable colorectal cancer. Translational Oncology, 48, 102064. (doi: 10.1016/j.tranon.2024.102064) (PMID:39068768)

Shamis, S. A.K. et al. (2024) Elucidation of dysregulated pathways associated with hypoxia in ER-negative breast cancer. Cancer Medicine, (Accepted for Publication)

Knight, K., Bigley, C., Pennel, K. , Hay, J., Maka, N., McMillan, D. , Park, J. , Roxburgh, C. and Edwards, J. (2024) The Glasgow Microenvironment Score: an exemplar of contemporary biomarker evolution in colorectal cancer. Journal of Pathology: Clinical Research, 10, e12385. (doi: 10.1002/2056-4538.12385) (PMID:38853386)

Thompson, J., McGovern, J., Roxburgh, C. , Edwards, J. , Dolan, R. D. and McMillan, D. C. (2024) The relationship between LDH and GLIM criteria for cancer cachexia: systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 199, 104378. (doi: 10.1016/j.critrevonc.2024.104378) (PMID:38754770)

McKenzie, M., Lian, G.-Y., Pennel, K. A.F., Quinn, J. A. , Jamieson, N. B. and Edwards, J. (2024) NFκB signalling in colorectal cancer: examining the central dogma of IKKα and IKKβ signalling. Heliyon, 10(12), e32904. (doi: 10.1016/j.heliyon.2024.e32904) (PMID:38975078) (PMCID:PMC11226910)

Hatthakarnkul, P. et al. (2024) Histopathological tumour microenvironment score independently predicts outcome in primary operable colorectal cancer. Journal of Pathology: Clinical Research, 10(3), e12374. (doi: 10.1002/2056-4538.12374) (PMID:38650367) (PMCID:PMC11035902)

Pennel, K., Dutton, L. , Melissourgou-Syka, L. , Roxburgh, C. , Birch, J. and Edwards, J. (2024) Novel radiation and targeted therapy combinations for improving rectal cancer outcomes. Expert Reviews in Molecular Medicine, 26, e14. (doi: 10.1017/erm.2024.15) (PMID:38623751) (PMCID:PMC11140547)

Domingo, E. et al. (2024) Prognostic and predictive value of Immunoscore in stage III colorectal cancer: pooled analysis of 2,608 cases from the SCOT and IDEA-HORG studies. Journal of Clinical Oncology, (doi: 10.1200/JCO.23.01648) (PMID:38484206) (Early Online Publication)

Pennel, K. A.F. et al. (2024) JAK/STAT3 represents a therapeutic target for colorectal cancer patients with stromal-rich tumors. Journal of Experimental and Clinical Cancer Research, 43, 64. (doi: 10.1186/s13046-024-02958-4)

Frei, A. L. et al. (2024) Multiplex analysis of intratumoural immune infiltrate and prognosis in patients with stage II–III colorectal cancer from the SCOT and QUASAR 2 trials: A retrospective analysis. Lancet Oncology, 25(2), pp. 198-211. (doi: 10.1016/S1470-2045(23)00560-0) (PMID:38301689)

Hillson, L. V. S., McCulloch, A. K., Edwards, J. , Dunne, P. D., O'Cathail, S. M. and Roxburgh, C. S. (2024) Radiation-induced changes in gene expression in rectal cancer specimens. Clinical and Translational Oncology, (doi: 10.1007/s12094-023-03361-9) (PMID:38243085) (Early Online Publication)

Brouwer, N.P.M. et al. (2024) The complexity of shapes: how the circularity of tumor nodules impacts prognosis in colorectal cancer. Modern Pathology, 37(1), 100376. (doi: 10.1016/j.modpat.2023.100376) (PMID:37926423)

Shamis, S. A. K., Savioli, F., Ammar, A. , Al-Badran, S. S.F., Hatthakarnkul, P., Leslie, H. , Mallon, E., Jamieson, N. B. , McMillan, D. C. and Edwards, J. (2024) Spatial transcriptomic analysis of tumour with high and low CAIX expression in TNBC tissue samples using GeoMx™ RNA assay. Histology and Histopathology: Cellular and Molecular Biology, 39, pp. 177-200. (doi: 10.14670/HH-18-655) (PMID:37681672)

2023

Beach, C. et al. (2023) Improving radiotherapy in immunosuppressive microenvironments by targeting complement receptor C5aR1. Journal of Clinical Investigation, 133(23), e168277. (doi: 10.1172/JCI168277) (PMID:37824211) (PMCID:PMC10688992)

Frei, A. L. et al. (2023) Accounting for intensity variation in image analysis of large-scale multiplexed clinical trial datasets. Journal of Pathology: Clinical Research, 9(6), pp. 449-463. (doi: 10.1002/cjp2.342) (PMID:37697694) (PMCID:PMC10556275)

Suzuki, T. et al. (2023) β-catenin drives butyrophilin-like molecule loss and γδ T-cell exclusion in colon cancer. Cancer Immunology Research, 11(8), pp. 1137-1155. (doi: 10.1158/2326-6066.CIR-22-0644) (PMID:37309673) (PMCID:PMC10398359)

Vande Voorde, J. et al. (2023) Metabolic profiling stratifies colorectal cancer and reveals adenosylhomocysteinase as a therapeutic target. Nature Metabolism, 5(8), pp. 1303-1318. (doi: 10.1038/s42255-023-00857-0) (PMID:37580540) (PMCID:PMC10447251)

Hatthakarnkul, P. et al. (2023) Protein expression of S100A2 reveals it association with patient prognosis and immune infiltration profile in colorectal cancer. Journal of Cancer, 14(10), pp. 1837-1847. (doi: 10.7150/jca.83910) (PMID:37476187) (PMCID:PMC10355195)

Johnstone, M. S., Stoops, R., Lynch, G., Hay, J., Jawny, J., Sloan, W., Edwards, J. and McSorley, S. T. (2023) Risk stratification for the detection of metachronous polyps after bowel screening polypectomy: clinical outcomes from the Integrated Technologies for Improved Polyp Surveillance (INCISE) study cohort. BJS Open, 7(3), zrad034. (doi: 10.1093/bjsopen/zrad034) (PMID:37158435) (PMCID:PMC10167706)

Pennel, K., Morrow, E., Hatthakarnkul, P., Leslie, H. , Mallon, E., Andersen, D., Jamieson, N. , McMillan, D. , Roseweir, A. and Edwards, J. (2023) High expression of STAT3 within the tumour-associated stroma predicts poor outcome in breast cancer patients. Cancer Medicine, 12(12), pp. 13225-13240. (doi: 10.1002/cam4.6014) (PMID:37199043) (PMCID:PMC10315752)

Shamis, S. A.K., Edwards, J. and McMillan, D. C. (2023) The relationship between carbonic anhydrase IX (CAIX) and patient survival in breast cancer: systematic review and meta-analysis. Diagnostic Pathology, 18, 46. (doi: 10.1186/s13000-023-01325-9) (PMID:37061698) (PMCID:PMC10105416)

Wood, C. S. et al. (2023) Spatially resolved transcriptomics deconvolutes prognostic histological subgroups in patients with colorectal cancer and synchronous liver metastases. Cancer Research, 83(8), pp. 1329-1344. (doi: 10.1158/0008-5472.CAN-22-2794) (PMID:37057593) (PMCID:PMC10102851)

Numprasit, W., Yangngam, S., Prasopsiri, J., Quinn, J. A. , Edwards, J. and Thuwajit, C. (2023) Carbonic anhydrase IX-related tumoral hypoxia predicts worse prognosis in breast cancer: a systematic review and meta-analysis. Frontiers in Medicine, 10, 1087270. (doi: 10.3389/fmed.2023.1087270) (PMID:37007798) (PMCID:PMC10063856)

Alexander, P.G., van Wyk, H.C. , Pennel, K.A.F., Hay, J., McMillan, D.C. , Horgan, P.G. , Roxburgh, C.S.D. , Edwards, J. and Park, J.H. (2023) The Glasgow Microenvironment Score and risk and site of recurrence in TNM I–III colorectal cancer. British Journal of Cancer, 128(4), pp. 556-567. (doi: 10.1038/s41416-022-02069-x) (PMID:36476660) (PMCID:PMC9938140)

Tandon, V., Moreno, R., Allmeroth, K., Quinn, J. , Wiley, S. E., Nicely, L. G., Denzel, M. S., Edwards, J. , de la Vega, L. and Banerjee, S. (2023) Dual inhibition of HSF1 and DYRK2 impedes cancer progression. Bioscience Reports, 34(1), BSR2022210. (doi: 10.1042/BSR20222102) (PMID:36622366) (PMCID:PMC9894012)

2022

Patel, M., McAllister, M., Nagaraju, R., Al Badran, S. S. F., Edwards, J. , McBain, A. J., Barriuso, J. and Aziz, O. (2022) The intestinal microbiota in colorectal cancer metastasis - Passive observer or key player? Critical Reviews in Oncology/Hematology, 180, 103856. (doi: 10.1016/j.critrevonc.2022.103856) (PMID:36257533)

Savioli, F., Morrow, E. S., Dolan, R. D. , Romics, L., Lannigan, A., Edwards, J. and McMillan, D. C. (2022) Prognostic role of preoperative circulating systemic inflammatory response markers in primary breast cancer: meta-analysis. British Journal of Surgery, 109(12), pp. 1206-1215. (doi: 10.1093/bjs/znac319) (PMID:36130112)

Pennel, K. A. F. et al. (2022) CXCL8 expression is associated with advanced stage, right sidedness, and distinct histological features of colorectal cancer. Journal of Pathology: Clinical Research, 8(6), pp. 509-520. (doi: 10.1002/cjp2.290) (PMID:35879507) (PMCID:PMC9535100)

Alexander, P. G. et al. (2022) The relationship between the Glasgow Microenvironment Score and markers of epithelial-mesenchymal transition in TNM II-III colorectal cancer. Human Pathology, 127, pp. 1-11. (doi: 10.1016/j.humpath.2022.05.012) (PMID:35623467)

Yangngam, S., Prasopsiri, J., Hatthakarnkul, P., Thongchot, S., Thuwajit, P., Yenchitsomanus, P.-t., Edwards, J. and Thuwajit, C. (2022) Cellular localization of nucleolin determines the prognosis in cancers: a meta-analysis. Journal of Molecular Medicine, 100(8), pp. 1145-1157. (doi: 10.1007/s00109-022-02228-w) (PMID:35861882) (PMCID:PMC9329415)

Shamis, S. A.K., Quinn, J. , Mallon, E. E.A., Edwards, J. and McMillan, D. C. (2022) The relationship between the tumor cell expression of hypoxic markers and survival in patients with ER-positive invasive ductal breast cancer. Journal of Histochemistry and Cytochemistry, 70(7), pp. 479-494. (doi: 10.1369/00221554221110280) (PMID:35792080)

Patel, M. et al. (2022) Spatial expression of IKK-alpha is associated with a differential mutational landscape and survival in primary colorectal cancer. British Journal of Cancer, 126(12), pp. 1704-1714. (doi: 10.1038/s41416-022-01729-2) (PMID:35173303) (PMCID:PMC9174220)

Hatthakarnkul, P., Quinn, J. A. , Ammar, A. , Lynch, G., Van Wyk, H. , McMillan, D. C. , Thuwajit, C. and Edwards, J. (2022) Molecular mechanisms of tumour budding and its association with microenvironment in colorectal cancer. Clinical Science, 136(8), pp. 521-535. (doi: 10.1042/CS20210886) (PMID:35445707)

Blomme, A. et al. (2022) THEM6‐mediated reprogramming of lipid metabolism supports treatment resistance in prostate cancer. EMBO Molecular Medicine, 14(3), e14764. (doi: 10.15252/emmm.202114764) (PMID:35014179) (PMCID:PMC8899912)

2021

Lampis, A. et al. (2021) MIR21-induced loss of junctional adhesion molecule A promotes activation of oncogenic pathways, progression and metastasis in colorectal cancer. Cell Death and Differentiation, 28, pp. 2970-2982. (doi: 10.1038/s41418-021-00820-0) (PMID:34226680) (PMCID:PMC8481293)

Hanna, C. R. et al. (2021) Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT). Radiation Oncology, 16, 163. (doi: 10.1186/s13014-021-01888-1) (PMID:34446053)

Johnstone, M. S., Lynch, G., Park, J. , McSorley, S. and Edwards, J. (2021) Novel methods of risk stratifying patients for metachronous, pre-malignant colorectal polyps: a systematic review. Critical Reviews in Oncology/Haematology, 164, 103421. (doi: 10.1016/j.critrevonc.2021.103421) (PMID:34246774)

Mansouri, D. , McSorley, S. T. , Park, J. H. , Orange, C., Horgan, P. G. , McMillan, D. C. and Edwards, J. (2021) The inflammatory microenvironment in screen-detected premaligant adenomatous polyps: early results from the integrated technologies for improved polyp surveillance (INCISE) project. European Journal of Gastroenterology and Hepatology, 33(7), pp. 983-989. (doi: 10.1097/MEG.0000000000002202) (PMID:34034277)

Matly, A., Quinn, J. A. , McMillan, D. C. , Park, J. H. and Edwards, J. (2021) The relationship between β-catenin and patient survival in colorectal cancer systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 163, 103337. (doi: 10.1016/j.critrevonc.2021.103337) (PMID:33992802)

Knight, J. R.P. et al. (2021) MNK inhibition sensitizes KRAS-mutant colorectal cancer to mTORC1 inhibition by reducing eIF4E phosphorylation and c-MYC expression. Cancer Discovery, 11(5), pp. 1228-1247. (doi: 10.1158/2159-8290.CD-20-0652) (PMID:33328217)

Moreno, R., Banerjee, S., Jackson, A. W., Quinn, J. , Baillie, G., Dixon, J. E., Dinkova-Kostova, A. T., Edwards, J. and de la Vega, L. (2021) The stress-responsive kinase DYRK2 activates heat shock factor 1 promoting resistance to proteotoxic stress. Cell Death and Differentiation, 28(5), pp. 1563-1578. (doi: 10.1038/s41418-020-00686-8) (PMID:33268814)

Al-Badran, S. S.F. et al. (2021) Relationship between immune checkpoint proteins, tumour microenvironment characteristics, and prognosis in primary operable colorectal cancer. Journal of Pathology: Clinical Research, 7(2), pp. 121-134. (doi: 10.1002/cjp2.193) (PMID:33338327)

Shamis, S. A. K., McMillan, D. C. and Edwards, J. (2021) The relationship between Hypoxia-inducible factor 1α (HIF-1α) and patient survival in breast cancer: systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 159, 103231. (doi: 10.1016/j.critrevonc.2021.103231) (PMID:33482350)

Alexander, P.G. et al. (2021) The Glasgow Microenvironment Score associates with prognosis and adjuvant chemotherapy response in colorectal cancer. British Journal of Cancer, 124, pp. 786-796. (doi: 10.1038/s41416-020-01168-x) (PMID:33223535)

Hatthakarnkul, P., Quinn, J. A. , Matly, A. A. M., Ammar, A. , Van Wyk, H. C. , McMillan, D. C. and Edwards, J. (2021) Systematic review of tumour budding and association with common mutations in patients with colorectal cancer. Critical Reviews in Oncology/Hematology, 167, 103490. (doi: 10.1016/j.critrevonc.2021.103490) (PMID:34619332)

2020

McAllister, M. J., McCall, P., Dickson, A., Underwood, M. A., Andersen, D., Holmes, E., Market, E., Leung, H. Y. and Edwards, J. (2020) Androgen receptor phosphorylation at serine 81 and serine 213 in castrate-resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 23(4), pp. 596-606. (doi: 10.1038/s41391-020-0235-1) (PMID:32358577)

McAllister, M., Constancio, V., Patek, S., Gan, H., Bailey, P. , Wheadon, H. , Underwood, M., Leung, H. and Edwards, J. (2020) Inflammatory infiltration is associated with AR expression and poor prognosis in hormone naïve prostate cancer. Prostate, 80(15), pp. 1353-1364. (doi: 10.1002/pros.24064) (PMID:32846021)

Savioli, F., Edwards, J. , McMillan, D. , Stallard, S., Doughty, J. and Romics, L. (2020) The effect of postoperative complications on survival and recurrence after surgery for breast cancer: a systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 155, 103075. (doi: 10.1016/j.critrevonc.2020.103075) (PMID:32987333)

Suzuki, T., Hayman, L., Kilbey, A., Edwards, J. and Coffelt, S. B. (2020) Gut γδ T cells as guardians, disruptors and instigators of cancer. Immunological Reviews, 298(1), pp. 198-217. (doi: 10.1111/imr.12916) (PMID:32840001)

Montes, M. et al. (2020) Determining the prognostic significance of IKKα in prostate cancer. Prostate, 80(14), pp. 1188-1202. (doi: 10.1002/pros.24045) (PMID:33258506)

Roseweir, A. K. et al. (2020) Histological phenotypic subtypes predict recurrence risk and response to adjuvant chemotherapy in patients with stage III colorectal cancer. Journal of Pathology: Clinical Research, 6(4), pp. 283-296. (doi: 10.1002/cjp2.171) (PMID:32401426) (PMCID:PMC7578335)

Torrente, L. et al. (2020) High NRF2 levels correlate with poor prognosis in colorectal cancer patients and with sensitivity to the kinase inhibitor AT9283 in vitro. Biomolecules, 10(10), 1365. (doi: 10.3390/biom10101365) (PMID:32992842) (PMCID:PMC7600603)

Rooney, N. et al. (2020) RUNX1 is a driver of renal cell carcinoma correlating with clinical outcome. Cancer Research, 80(11), pp. 2325-2339. (doi: 10.1158/0008-5472.CAN-19-3870) (PMID:32156779)

Patel, R. et al. (2020) Activation of β-catenin cooperates with loss of Pten to drive AR-independent castration-resistant prostate cancer. Cancer Research, 80(3), pp. 576-590. (doi: 10.1158/0008-5472.CAN-19-1684) (PMID:31719098)

Loveridge, C. J. et al. (2020) BRF1 accelerates prostate tumourigenesis and perturbs immune infiltration. Oncogene, 39, pp. 1797-1806. (doi: 10.1038/s41388-019-1106-x) (PMID:31740786) (PMCID:PMC7033044)

2019

Park, J. H. , van Wyk, H. , McMillan, D. C. , Edwards, J. , Orange, C., Horgan, P. G. and Roxburgh, C. S.D. (2019) Pre-operative, biopsy-based assessment of the tumour microenvironment in patients with primary operable colorectal cancer. Journal of Pathology: Clinical Research, 6(1), pp. 30-39. (doi: 10.1002/cjp2.143) (PMID:31486287) (PMCID:PMC6966701)

Andisha, N. M., McMillan, D. C. , Gujam, F. J.A., Roseweir, A. and Edwards, J. (2019) The relationship between phosphorylation status of focal adhesion kinases, molecular subtypes, tumour microenvironment and survival in patients with primary operable ductal breast cancer. Cellular Signalling, 60, pp. 91-99. (doi: 10.1016/j.cellsig.2019.04.006) (PMID:30981841)

Khongthong, P., Roseweir, A. K. and Edwards, J. (2019) The NF-KB pathway and endocrine therapy resistance in breast cancer. Endocrine-Related Cancer, 26(6), R369-R380. (doi: 10.1530/ERC-19-0087) (PMID:32013374)

Roseweir, A. K. , Clark, J., McSorley, S. T. , vanWyk, H. C. , Quinn, J. A. , Horgan, P. G. , McMillan, D. C. , Park, J. H. and Edwards, J. (2019) The association between markers of tumour cell metabolism, the tumour microenvironment and outcomes in patients with colorectal cancer. International Journal of Cancer, 144(9), pp. 2320-2329. (doi: 10.1002/ijc.32045) (PMID:30521130)

McAllister, M. J., Underwood, M. A., Leung, H. Y. and Edwards, J. (2019) A review on the interactions between the tumour microenvironment and androgen receptor signaling in prostate cancer. Translational Research, 206, pp. 91-106. (doi: 10.1016/j.trsl.2018.11.004) (PMID:30528321)

Roseweir, A. K. , Powell, A. G.M.T., Horstman, S. L., Inthagard, J., Park, J. A. , McMillan, D. C. , Horgan, P. G. and Edwards, J. (2019) Src family kinases, HCK and FGR, associate with local inflammation and tumour progression in colorectal cancer. Cellular Signalling, 56, pp. 15-22. (doi: 10.1016/j.cellsig.2019.01.007) (PMID:30684564)

Pennel, K. A.F., Park, J. H. , McMillan, D. C. , Roseweir, A. K. and Edwards, J. (2019) Signal interaction between the tumour and inflammatory cells in patients with gastrointestinal cancer: implications for treatment. Cellular Signalling, 54, pp. 81-90. (doi: 10.1016/j.cellsig.2018.11.013) (PMID:30453014)

Inthagard, J., Edwards, J. and Roseweir, A. K. (2019) Immunotherapy: enhancement the efficacy of this promising therapeutic in multiple cancers. Clinical Science, 133(2), pp. 181-193. (doi: 10.1042/CS20181003) (PMID:30659159)

Morrow, E., Roseweir, A. and Edwards, J. (2019) The role of gamma delta T lymphocytes in breast cancer: a review. Translational Research, 203, pp. 88-96. (doi: 10.1016/j.trsl.2018.08.005) (PMID:30194922)

Roseweir, A.K. et al. (2019) A novel tumor-based epithelial-to-mesenchymal transition score that associates with prognosis and metastasis in patients with stage II/III colorectal cancer. International Journal of Cancer, 144(1), pp. 150-159. (doi: 10.1002/ijc.31739) (PMID:29992570)

Van Wyk, H. , Roseweir, A. , Alexander, P. , Park, J. H. , Horgan, P. , McMillan, D. and Edwards, J. (2019) The relationship between tumour budding, tumour microenvironment and survival in patients with primary operable colorectal cancer. Annals of Surgical Oncology, 26, pp. 4397-4404. (doi: 10.1245/s10434-019-07931-6) (PMID:31605345) (PMCID:PMC6863941)

2018

Mulholland, T., McAllister, M., Patek, S., Flint, D., Underwood, M., Sim, A., Edwards, J. and Zagnoni, M. (2018) Drug screening of biopsy-derived spheroids using a self-generated microfluidic concentration gradient. Scientific Reports, 8, 14672. (doi: 10.1038/s41598-018-33055-0) (PMID:30279484) (PMCID:PMC6168499)

Roseweir, A. K. , McMillan, D. C. and Edwards, J. (2018) Reply to comment of "ERK and p38MAPK combine to improve survival in patients with BRAF mutant colorectal cancer". British Journal of Cancer, 119(7), p. 909. (doi: 10.1038/s41416-018-0275-7) (PMID:30297771) (PMCID:PMC6189185)

Paul, A., Edwards, J. , Pepper, C. and Mackay, S. (2018) Inhibitory-κB kinase (IKK) α and nuclear factor-κB (NFκB)-inducing kinase (NIK) as anti-cancer drug targets. Cells, 7(10), 176. (doi: 10.3390/cells7100176) (PMID:30347849) (PMCID:PMC6210445)

Lua, J., Qayyum, T., Edwards, J. and Roseweir, A. K. (2018) The prognostic role of the non-canonical nuclear factor-kappa B pathway in renal cell carcinoma patients. Urologia Internationalis, 101(2), pp. 190-196. (doi: 10.1159/000489816) (PMID:30089311)

Gujam, F., Dickson, K., McCall, P., McMillan, D. and Edwards, J. (2018) The relationship between androgen receptor, components of tumour microenvironment and survival in breast cancer molecular subtypes. Cancer Therapy and Oncology, 11(3), 555814.

Roseweir, A. K. , Halcrow, E. S., Chichilo, S., Powell, A. G.M.T., McMillan, D. C. , Horgan, P. G. and Edwards, J. (2018) ERK and p38MAPK combine to improve survival in patients with BRAF mutant colorectal cancer. British Journal of Cancer, 119, pp. 323-329. (doi: 10.1038/s41416-018-0174-y) (PMID:29988110) (PMCID:PMC6070918)

Patel, M., Horgan, P. G. , McMillan, D. C. and Edwards, J. (2018) NF-κB pathways in the development and progression of colorectal cancer. Translational Research, 197, pp. 43-56. (doi: 10.1016/j.trsl.2018.02.002) (PMID:29550444)

Roseweir, A. K. et al. (2018) Predictive biomarkers for endocrine therapy: retrospective study in Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trial. Journal of the National Cancer Institute, 110(6), pp. 616-627. (doi: 10.1093/jnci/djx255) (PMID:29917140)

Patel, R. et al. (2018) Sprouty2 loss‐induced IL6 drives castration‐resistant prostate cancer through scavenger receptor B1. EMBO Molecular Medicine, 10(4), e8347. (doi: 10.15252/emmm.201708347) (PMID:29540470) (PMCID:PMC5887544)

Patel, M., McSorley, S. T. , Park, J. H. , Roxburgh, C. S.D. , Edwards, J. , Horgan, P. G. and McMillan, D. C. (2018) The relationship between right-sided tumour location, tumour microenvironment, systemic inflammation, adjuvant therapy and survival in patients undergoing surgery for colon and rectal cancer. British Journal of Cancer, 118(5), pp. 705-712. (doi: 10.1038/bjc.2017.441) (PMID:29337962) (PMCID:PMC5846060)

Campbell, K. J. et al. (2018) MCL-1 is a prognostic indicator and drug target in breast cancer. Cell Death and Disease, 9, 19. (doi: 10.1038/s41419-017-0035-2) (PMID:29339815) (PMCID:PMC5833338)

Bilsland, A. , Kelly, C. , Roccisana, J., Paul, J. , Jones, R. , Edwards, J. , Roseweir, A. , Stein, T. and West, K. (2018) An Exploratory Study on the Use of Game-based Learning Using Microsoft Kinect to Teach Oncology Phase I Clinical Trial Designs. 2018 NCRI Cancer Conference, Glasgow, UK, 04-06 Nov 2018. (doi: 10.1038/s41416-018-0299-z)

McClurg, U. L., Chit, N. C.T.H., Azizyan, M., Edwards, J. , Nabbi, A., Riabowol, K. T., Nakjang, S., McCracken, S. R. and Robson, C. N. (2018) Molecular mechanism of the TP53-MDM2-AR-AKT signalling network regulation by USP12. Oncogene, 37, pp. 4679-4691. (doi: 10.1038/s41388-018-0283-3) (PMID:29755129)

Sierra Gonzalez, P. et al. (2018) Mannose impairs tumour growth and enhances chemotherapy. Nature, 563, pp. 719-723. (doi: 10.1038/s41586-018-0729-3) (PMID:30464341)

2017

Anthony, N. G. et al. (2017) Inhibitory Kappa B kinse α (IKKα) inhibitors that recapitulate their selectivity in cells against isoform-related biomarkers. Journal of Medicinal Chemistry, 60(16), pp. 7043-7066. (doi: 10.1021/acs.jmedchem.7b00484) (PMID:28737909) (PMCID:PMC5578373)

Park, J. H. , Roxburgh, C. S.D. , Edwards, J. , Horgan, P. G. and McMillan, D. C. (2017) In reply to "Hynes S.O. et al. Back to the future: routine morphological assessment of the tumour microenvironment is prognostic in stage II/III colon cancer in a large population-based study". Histopathology, 71(2), pp. 326-327. (doi: 10.1111/his.13195) (PMID:28226191)

Roseweir, A. K. , McCall, P., Scott, A., Liew, B., Lim, Z., Mallon, E. A. and Edwards, J. (2017) Phosphorylation of androgen receptors at serine 515 is a potential prognostic marker for triple negative breast cancer. Oncotarget, 8(23), pp. 37172-37185. (doi: 10.18632/oncotarget.16420) (PMID:28415597) (PMCID:PMC5514900)

Roseweir, A. K. , McMillan, D. C. , Horgan, P. G. and Edwards, J. (2017) Colorectal cancer subtypes: Translation to routine clinical pathology. Cancer Treatment Reviews, 57, pp. 1-7. (doi: 10.1016/j.ctrv.2017.04.006) (PMID:28505475)

Park, J.H. , Van Wyk, H. , Roxburgh, C.S.D. , Horgan, P.G. , Edwards, J. and McMillan, D.C. (2017) Tumour invasiveness, the local and systemic environment and the basis of staging systems in colorectal cancer. British Journal of Cancer, 116, pp. 1444-1450. (doi: 10.1038/bjc.2017.108)

Bennett, L., Mallon, E. A., Horgan, P. G. , Paul, A., McMillan, D. C. and Edwards, J. (2017) The relationship between members of the canonical NF-KB pathway, components of tumour microenvironment and survival in patients with invasive ductal breast cancer. Oncotarget, 8(20), pp. 33002-33013. (doi: 10.18632/oncotarget.16031) (PMID:28423692)

Dreyer, S. B., Powell, A. G.M.T., McSorley, S. T. , Waterston, A., Going, J. J., Edwards, J. , McMillan, D. C. and Horgan, P. G. (2017) The pretreatment systemic inflammatory response is an important determinant of poor pathologic response for patients undergoing neoadjuvant therapy for rectal cancer. Annals of Surgical Oncology, 24(5), pp. 1295-1303. (doi: 10.1245/s10434-016-5684-3) (PMID:27873100)

Bennett, L., Quinn, J. , McCall, P., Mallon, E. A., Horgan, P. G. , McMillan, D. C. , Paul, A. and Edwards, J. (2017) High IKKα expression is associated with reduced time to recurrence and cancer specific survival in oestrogen receptor (ER)-positive breast cancer. International Journal of Cancer, 140(7), pp. 1633-1644. (doi: 10.1002/ijc.30578) (PMID:28006839)

Cheng, K. K.W., Dickson, A., Gujam, F. J.A., McMillan, D. C. and Edwards, J. (2017) The relationship between oestrogen receptor-alpha phosphorylation and the tumour microenvironment in patients with primary operable ductal breast cancer. Histopathology, 70(5), pp. 782-797. (doi: 10.1111/his.13134) (PMID:27891654)

Park, J. H. , Van Wyk, H. C., McMillan, D. C. , Quinn, J. A. , Clark, J., Roxburgh, C. , Horgan, P. G. and Edwards, J. (2017) Signal transduction and activator of transcription-3 (STAT3) in patients with colorectal cancer: associations with the phenotypic features of the tumour and host. Clinical Cancer Research, 23(7), pp. 1698-1709. (doi: 10.1158/1078-0432.CCR-16-1416) (PMID:27678454)

Diaz-Vera, J., Palmer, S., Hernandez-Fernaud, J. R., Dornier, E., Mitchell, L. E., MacPherson, I. , Edwards, J. , Zanivan, S. and Norman, J. C. (2017) A proteomic approach to identify endosomal cargoes controlling cancer invasiveness. Journal of Cell Science, 130(4), pp. 697-711. (doi: 10.1242/jcs.190835) (PMID:28062852)

2016

Patek, S.C., Willder, J.M., Heng, J.S., Taylor, B., Horgan, P.G. , Leung, H.Y. , Underwood, M.A. and Edwards, J. (2016) Androgen receptor phosphorylation status at serine 578 predicts poor outcome in prostate cancer patients. Oncotarget, 8(3), pp. 4875-4887. (doi: 10.18632/oncotarget.13608) (PMID:27902483)

Hatziieremia, S., Mohammed, Z., McCall, P., Willder, J. M., Roseweir, A. K. , Underwood, M. A. and Edwards, J. (2016) Loss of signal transducer and activator of transcription 1 is associated with prostate cancer recurrence. Molecular Carcinogenesis, 55(11), pp. 1667-1677. (doi: 10.1002/mc.22417) (PMID:26495772)

Gujam, F. J.A., McMillan, D. C. and Edwards, J. (2016) The relationship between total and phosphorylated STAT1 and STAT3 tumour cell expression, components of tumour microenvironment and survival in patients with invasive ductal breast cancer. Oncotarget, 7(47), pp. 77607-77621. (doi: 10.18632/oncotarget.12730) (PMID:27769057)

Campbell, E. J., Tesson, M., Doogan, F., Mohammed, Z. M.A., Mallon, E. and Edwards, J. (2016) The combined endocrine receptor in breast cancer, a novel approach to traditional hormone receptor interpretation and a better discriminator of outcome than ER and PR alone. British Journal of Cancer, 115(8), pp. 967-973. (doi: 10.1038/bjc.2016.206) (PMID:27657341)

Roseweir, A. K. , Powell, A. G.M.T., Bennett, L., Van Wyk, H. C. , Park, J. , McMillan, D. C. , Horgan, P. G. and Edwards, J. (2016) Relationship between tumour PTEN/Akt/COX-2 expression, inflammatory response and survival in patients with colorectal cancer. Oncotarget, 7(43), pp. 70601-70612. (doi: 10.18632/oncotarget.12134) (PMID:27661110)

Ahmad, I. et al. (2016) Sleeping Beauty screen reveals Pparg activation in metastatic prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 113(29), pp. 8290-8295. (doi: 10.1073/pnas.1601571113) (PMID:27357679) (PMCID:PMC4961202)

van Wyk, H. C. , Park, J. H. , Edwards, J. , Horgan, P. G. , McMillan, D. C. and Going, J. J. (2016) The relationship between tumour budding, the tumour microenvironment and survival in patients with primary operable colorectal cancer. British Journal of Cancer, 115(2), pp. 156-163. (doi: 10.1038/bjc.2016.173) (PMID:27299960)

Park, J. H. , McMillan, D. C. , Edwards, J. , Horgan, P. G. and Roxburgh, C. S.D. (2016) Comparison of the prognostic value of measures of the tumor inflammatory cell infiltrate and tumor-associated stroma in patients with primary operable colorectal cancer. OncoImmunology, 5(3), e1098801. (doi: 10.1080/2162402X.2015.1098801)

Park, J. H. , Powell, A. G., Roxburgh, C. S.D. , Horgan, P. G. , McMillan, D. c. and Edwards, J. (2016) Mismatch repair status in patients with primary operable colorectal cancer: associations with the local and systemic tumour environment. British Journal of Cancer, 114, pp. 562-570. (doi: 10.1038/bjc.2016.17) (PMID:26859693)

Roseweir, A. K. , Qayyum, T., Lim, Z., Hammond, R., MacDonald, A. I., Fraser, S., Oades, G. M., Aitchison, M., Jones, R. J. and Edwards, J. (2016) Nuclear expression of Lyn, a Src family kinase member, is associated with poor prognosis in renal cancer patients. BMC Cancer, 16, p. 229. (doi: 10.1186/s12885-016-2254-9) (PMID:26984511) (PMCID:PMC4794832)

2015

Gujam, F.J.A., McMillan, D.C. , Mohammed, Z.M.A., Edwards, J. and Going, J.J. (2015) The relationship between tumour budding, the tumour microenvironment and survival in patients with invasive ductal breast cancer. British Journal of Cancer, 113(7), pp. 1066-1074. (doi: 10.1038/bjc.2015.287) (PMID:26263482)

Park, J. H. , McMillan, D. C. , Powell, A. G., Richards, C. H., Horgan, P. G. , Edwards, J. and Roxburgh, C. S.D. (2015) Evaluation of a tumor microenvironment-based prognostic score in primary operable colorectal cancer. Clinical Cancer Research, 21(4), pp. 882-888. (doi: 10.1158/1078-0432.CCR-14-1686) (PMID:25473000)

Mardilovich, K., Gabrielsen, M. , McGarry, L., Orange, C., Patel, R., Shanks, E., Edwards, J. and Olson, M. F. (2015) Elevated LIM kinase 1 in nonmetastatic prostate cancer reflects its role in facilitating androgen receptor nuclear translocation. Molecular Cancer Therapeutics, 14(1), pp. 246-258. (doi: 10.1158/1535-7163.MCT-14-0447)

2014

MacPherson, I. R. et al. (2014) CLIC3 controls recycling of late endosomal MT1-MMP and dictates invasion and metastasis in breast cancer. Journal of Cell Science, 127(18), pp. 3893-3901. (doi: 10.1242/jcs.135947) (PMID:25015290)

Rajan, P. et al. (2014) Next-generation sequencing of advanced prostate cancer treated with androgen-deprivation therapy. European Urology, 66(1), pp. 32-39. (doi: 10.1016/j.eururo.2013.08.011) (PMID:24054872) (PMCID:PMC4062940)

Ferrari, N., Mohammed, Z. M. A., Nixon, C., Mason, S. M., Mallon, E., McMillan, D. C. , Morris, J. S. , Cameron, E. R. , Edwards, J. and Blyth, K. (2014) Expression of RUNX1 correlates with poor patient prognosis in triple negative breast cancer. PLoS ONE, 9(6), e100759. (doi: 10.1371/journal.pone.0100759) (PMID:24967588) (PMCID:PMC4072705)

McDonald, L. et al. (2014) RUNX2 correlates with subtype-specific breast cancer in a human tissue microarray, and ectopic expression of Runx2 perturbs differentiation in the mouse mammary gland. Disease Models and Mechanisms, 7(5), pp. 525-534. (doi: 10.1242/dmm.015040)

Gujam, F.J.A., Going, J.J., Edwards, J. , Mohammed, Z.M.A. and McMillan, D.C. (2014) The role of lymphatic and blood vessel invasion in predicting survival and methods of detection in patients with primary operable breast cancer. Critical Reviews in Oncology/Hematology, 89(2), pp. 231-241. (doi: 10.1016/j.critrevonc.2013.08.014)

McGlynn, L.M. et al. (2014) SIRT2: Tumour suppressor or tumour promoter in operable breast cancer? European Journal of Cancer, 50(2), pp. 290-301. (doi: 10.1016/j.ejca.2013.10.005) (PMID:24183459)

Gujam, F.J.A., Edwards, J. , Mohammed, Z.M.A., Going, J.J. and McMillan, D.C. (2014) The relationship between the tumour stroma percentage, clinicopathological characteristics and outcome in patients with operable ductal breast cancer. British Journal of Cancer, 111(1), pp. 157-165. (doi: 10.1038/bjc.2014.279)

Gujam, F. J.A., Going, J. J., Mohammed, Z. M.A., Orange, C., Edwards, J. and McMillan, D. C. (2014) Immunohistochemical detection improves the prognostic value of lymphatic and blood vessel invasion in primary ductal breast cancer. BMC Cancer, 14(1), p. 676. (doi: 10.1186/1471-2407-14-676)

2013

Powell, A.G.M.T., Ferguson, J., Al-Mulla, F., Orange, C., McMillan, D.C. , Horgan, P.G. , Edwards, J. and Going, J.J. (2013) The relationship between genetic profiling, clinicopathological factors and survival in patients undergoing surgery for node-negative colorectal cancer: 10-year follow-up. Journal of Cancer Research and Clinical Oncology, 139(12), pp. 2013-2020. (doi: 10.1007/s00432-013-1521-2)

Vijayan, A. et al. (2013) IGFBP-5 enhances epithelial cell adhesion and protects epithelial cells from TGFβ1-induced mesenchymal invasion. International Journal of Biochemistry and Cell Biology, 45(12), pp. 2774-2785. (doi: 10.1016/j.biocel.2013.10.001)

Rutherford, C. et al. (2013) Regulation of cell survival by sphingosine-1-phosphate receptor S1P1 via reciprocal ERK-dependent suppression of bim and PI-3-kinase/protein kinase C-mediated upregulation of Mcl-1. Cell Death and Disease, 4(11), e927. (doi: 10.1038/cddis.2013.455)

McCall, P., Adams, C.E., Willder, J., Bennett, L., Qayyum, T., Orange, C., Underwood, M. and Edwards, J. (2013) Androgen receptor phosphorylation at serine 308 and serine 791 predicts enhanced survival in castrate resistant prostate cancer patients. International Journal of Molecular Sciences, 14(8), pp. 16656-16671. (doi: 10.3390/ijms140816656) (PMID:23945560) (PMCID:PMC3759930)

Mohammed, Z.M.A., Orange, C., McMillan, D.C. , Mallon, E., Doughty, J.C., Edwards, J. and Going, J.J. (2013) Comparison of visual and automated assessment of microvessel density and their impact on outcome in primary operable invasive ductal breast cancer. Human Pathology, 44(8), pp. 1688-1695. (doi: 10.1016/j.humpath.2012.11.023)

Denley, S.M., Jamieson, N.B. , McCall, P., Oien, K.C.S. , Morton, J.P. , Carter, C.R., Edwards, J. and McKay, C.J. (2013) Activation of the IL-6R/Jak/Stat pathway is associated with a poor outcome in resected pancreatic ductal adenocarcinoma. Journal of Gastrointestinal Surgery, 17(5), pp. 887-898. (doi: 10.1007/s11605-013-2168-7)

McGlynn, L.M., Tovey, S., Bartlett, J.M.S., Doughty, J., Cooke, T.G. and Edwards, J. (2013) Interactions between MAP kinase and oestrogen receptor in human breast cancer. European Journal of Cancer, 49(6), pp. 1176-1186. (doi: 10.1016/j.ejca.2012.11.020)

Patel, R. et al. (2013) Sprouty2, PTEN, and PP2A interact to regulate prostate cancer progression. Journal of Clinical Investigation, 123(3), pp. 1157-1175. (doi: 10.1172/JCI63672)

Ohotski, J., Edwards, J. , Elsberger, B., Watson, C., Orange, C., Mallon, E., Pyne, S. and Pyne, N.J. (2013) Identification of novel functional and spatial associations between sphingosine kinase 1, sphingosine 1-phosphate receptors and other signaling proteins that affect prognostic outcome in estrogen receptor-positive breast cancer. International Journal of Cancer, 132(3), pp. 605-616. (doi: 10.1002/ijc.27692)

Willder, J.M. et al. (2013) Androgen receptor phosphorylation at serine 515 by Cdk1 predicts biochemical relapse in prostate cancer patients. British Journal of Cancer, 108(1), pp. 139-148. (doi: 10.1038/bjc.2012.480)

Roxburgh, C.S. , Richards, C.H., MacDonald, A.I., Powell, A.G., McGlynn, L.M., McMillan, D.C. , Horgan, P.G. , Edwards, J. and Shiels, P.G. (2013) The in situ local immune response, tumour senescence and proliferation in colorectal cancer. British Journal of Cancer, 109(8), pp. 2207-2216. (doi: 10.1038/bjc.2013.556)

2012

Sebastián, C. et al. (2012) The histone deacetylase SIRT6 is a novel tumor suppressor that controls cancer metabolism. Cell, 151(6), pp. 1185-1199. (doi: 10.1016/j.cell.2012.10.047) (PMID:23217706) (PMCID:PMC3526953)

Mohammed, Z.M.A., Going, J.J., Edwards, J. and McMillan, D.C. (2012) The role of the tumour inflammatory cell infiltrate in predicting recurrence and survival in patients with primary operable breast cancer. Cancer Treatment Reviews, 38(8), pp. 943-955. (doi: 10.1016/j.ctrv.2012.04.011)

Powell, A.G., Wallace, R., McKee, R.F., Anderson, J.H., Going, J.J., Edwards, J. and Horgan, P.G. (2012) The relationship between tumour site, clinicopathological characteristics and cancer-specific survival in patients undergoing surgery for colorectal cancer. Colorectal Disease, 14(12), pp. 1493-1499. (doi: 10.1111/j.1463-1318.2012.03048.x)

Mohammed, Z.M.A., Going, J.J., McMillan, D.C. , Orange, C., Mallon, E., Doughty, J.C. and Edwards, J. (2012) Comparison of visual and automated assessment of HER2 status and their impact on outcome in primary operable invasive ductal breast cancer. Histopathology, 61(4), pp. 675-684. (doi: 10.1111/j.1365-2559.2012.04280.x)

Mohammed, Z.M.A., Edwards, J. , Orange, C., Mallon, E., Doughty, J., McMillan, D.C. and Going, J.J. (2012) Breast cancer outcomes by steroid hormone receptor status assessed visually and by computer image analysis. Histopathology, 61(2), pp. 283-292. (doi: 10.1111/j.1365-2559.2012.04244.x)

Ohotski, J., Long, J.S., Orange, C., Elsberger, B., Doughty, J., Pyne, S., Pyne, N.J. and Edwards, J. (2012) Expression of sphingosine 1-phosphate receptor 4 and sphingosine kinase 1 is associated with outcome in oestrogen receptor-negative breast cancer. British Journal of Cancer, 106(8), pp. 1453-1459. (doi: 10.1038/bjc.2012.98)

Powell, A.G.M.T., Edwards, J. and Horgan, P.G. (2012) A move towards individualisation of patient treatment regimens in colorectal cancer. Colorectal Disease, 14(2), pp. 255-256. (doi: 10.1111/j.1463-1318.2011.02818.x)

Pyne, N. J., Tonelli, F., Lim, K. G., Long, J., Edwards, J. and Pyne, S. (2012) Targeting sphingosine kinase 1 in cancer. Advances in Biological Regulation, 52(1), pp. 31-38. (doi: 10.1016/j.advenzreg.2011.07.001)

Dutta, S., Going, J.J., Crumley, A.B.C., Mohammed, Z., Orange, C., Edwards, J. , Fullarton, G.M., Horgan, P.G. and McMillan, D.C. (2012) The relationship between tumour necrosis, tumour proliferation, local and systemic inflammation, microvessel density and survival in patients undergoing potentially curative resection of oesophageal adenocarcinoma. British Journal of Cancer, 106(4), pp. 702-710. (doi: 10.1038/bjc.2011.610)

Elsberger, B., Paravasthu, D.M., Tovey, S.M. and Edwards, J. (2012) Shorter disease-specific survival of ER-positive breast cancer patients with high cytoplasmic Src kinase expression after tamoxifen treatment. Journal of Cancer Research and Clinical Oncology, 138(2), pp. 327-332. (doi: 10.1007/s00432-011-1096-8)

Hu, R. et al. (2012) Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Research, 72(14), pp. 3457-3462. (doi: 10.1158/0008-5472.CAN-11-3892)

McCall, P. et al. (2012) NFκB signalling is upregulated in a subset of castrate-resistant prostate cancer patients and correlates with disease progression. British Journal of Cancer, 107(9), pp. 1554-1563. (doi: 10.1038/bjc.2012.372)

Mohammed, Z.M.A., Going, J.J., Edwards, J. , Elsberger, B., Doughty, J.C. and McMillan, D.C. (2012) The relationship between components of tumour inflammatory cell infiltrate and clinicopathological factors and survival in patients with primary operable invasive ductal breast cancer. British Journal of Cancer, 107(5), pp. 864-873. (doi: 10.1038/bjc.2012.347)

Mohammed, Z.M.A., McMillan, D.C. , Elsberger, B., Going, J.J., Orange, C., Mallon, E., Doughty, J.C. and Edwards, J. (2012) Comparison of visual and automated assessment of Ki-67 proliferative activity and their impact on outcome in primary operable invasive ductal breast cancer. British Journal of Cancer, 106(2), pp. 383-388. (doi: 10.1038/bjc.2011.569)

Powell, A.G.M.T., Edwards, J. and Horgan, P.G. (2012) A move towards individualization of patient treatment regimens in colorectal cancer. Colorectal Disease, 14(2), pp. 255-256. (doi: 10.1111/j.1463-1318.2011.02818.x)

Powell, A.G.M.T., Horgan, P.G. and Edwards, J. (2012) The bodies fight against cancer: is human leucocyte antigen (HLA) class 1 the key? Journal of Cancer Research and Clinical Oncology, 138(5), pp. 723-728. (doi: 10.1007/s00432-012-1192-4)

Pyne, N.J., Tonelli, F., Lim, K.G., Long, J.S., Edwards, J. and Pyne, S. (2012) Sphingosine 1-phosphate signalling in cancer. Biochemical Society Transactions, 40(1), pp. 94-100. (doi: 10.1042/BST20110602)

Qayyum, T. et al. (2012) The interrelationships between Src, Cav-1 and RhoGD12 in transitional cell carcinoma of the bladder. British Journal of Cancer, 106(6), pp. 1187-1195. (doi: 10.1038/bjc.2012.52)

Qayyum, T. et al. (2012) Abstracts of the 10th International Kidney Cancer Symposium: The role of Src kinase in renal cell cancer. BJU International, 109(S5), p. 10. (doi: 10.1111/j.1464-410X.2012.11171.x)

Qayyum, T., McArdle, P.A., Going, J.J., Orange, C., Seywright, M., Aitchison, M.A. and Edwards, J. (2012) Is the presence or absence of tumour necrosis a significant predictor of survival in renal cell cancer? Urologia Internationalis, 88(1), pp. 79-83. (doi: 10.1159/000332430)

Qayyum, T., McArdle, P.A., Lamb, G.W., Going, J.J., Horgan, P.G. , Oades, G., Aitchison, M.A. and Edwards, J. (2012) Prospective study of the role of inflammation in renal cancer. Urologia Internationalis, 88(3), pp. 277-281. (doi: 10.1159/000334971)

Qayyum, T. et al. (2012) Expression and prognostic significance of Src family members in renal clear cell carcinoma. British Journal of Cancer, 107(5), pp. 856-863. (doi: 10.1038/bjc.2012.314)

2011

Marsella-Hatziieremia, S., McCall, P. and Edwards, J. (2011) Signalling pathways and gene expression profiles in prostate cancer. In: Spiess, P. (ed.) Prostate Cancer: From Bench to Bedside. InTech, pp. 93-114. ISBN 9789533073316 (doi: 10.5772/26971)

Armstrong, K., Ahmad, I. , Kalna, G., Tan, S.S., Edwards, J. , Robson, C.N. and Leung, H.Y. (2011) Upregulated FGFR1 expression is associated with the transition of hormone-naive to castrate-resistant prostate cancer. British Journal of Cancer, 105(9), pp. 1362-1369. (doi: 10.1038/bjc.2011.367)

Crumley, A.B.C., Going, J.J., Hilmy, M., Dutta, S., Tannahill, C., McKernan, M., Edwards, J. , Stuart, R.C. and McMillan, D.C. (2011) Interrelationships between tumor proliferative activity, leucocyte and macrophage infiltration, systemic inflammatory response, and survival in patients selected for potentially curative resection for gastroesophageal cancer. Annals of Surgical Oncology, 18(9), pp. 2604-2612. (doi: 10.1245/s10434-011-1658-7)

Elsberger, B., Lankston, L., McMillan, D.C. , Underwood, M.A. and Edwards, J. (2011) Presence of tumoural C-reactive protein correlates with progressive prostate cancer. Prostate Cancer and Prostatic Diseases, 14(2), pp. 122-128. (doi: 10.1038/pcan.2011.5)

Grimsley, S.J.S., Shini, S., Underwood, M.A. and Edwards, J. (2011) Heregulin expression and prognosis in prostate adenocarcinoma. Urologia Internationalis, 87(3), pp. 363-368. (doi: 10.1159/000328627)

McCall, P.,, Catlow, J., McArdle, P.A., McMillan, D.C. and Edwards, J. (2011) Tumoral C-reactive protein and nuclear factor kappa-B expression are associated with clinical outcome in patients with prostate cancer. Cancer Biomarkers, 10(2), pp. 91-99. (doi: 10.3233/CBM-2012-0236)

Mohammed, Z., Edwards, J. , Orange, C., Mallon, E.A., McMillan, D.C. and Going, J.J. (2011) Breast cancer survival stratified by automated versus visual analysis of ER and PR immunohistochemistry. Journal of Pathology, 224(S2), S4. (doi: 10.1002/path.2957)

Mukherjee, R., Mcguinness, D.H. , McCall, P., Underwood, M. A., Seywright, M., Orange, C. and Edwards, J. (2011) Upregulation of MAPK pathway is associated with survival in castrate-resistant prostate cancer. British Journal of Cancer, 104(12), pp. 1920-1928. (doi: 10.1038/bjc.2011.163) (PMID:21559022) (PMCID:PMC3111196)

Qayyum, T.Q., McArdle, P.A., Seywright, M., McMillan, D.C. , Aitchison, M.A. and Edwards, J. (2011) The role of Src in renal cancer. British Journal of Surgery, 98(S2), p. 50. (doi: 10.1002/bjs.7523)

2010

Teo, K., McVitty, C., Mitchell, T., McCall, P. and Edwards, J. (2010) Cyclin D1 expression influences overall survival in androgen independent prostate cancer. British Journal of Cancer, 97(S6), p. 26. (doi: 10.1002/bjs.7351)

Watson, C., Long, J.S., Orange, C., Tannahill, C.L., Mallon, E., McGlynn, L.M., Pyne, S., Pyne, N.J. and Edwards, J. (2010) High expression of sphingosine 1-phosphate receptors, S1P1 and S1P3, sphingosine kinase 1, and extracellular signal-regulated kinase-1/2 is associated with development of tamoxifen resistance in estrogen receptor-positive breast cancer patients. American Journal of Pathology, 177(5), pp. 2205-2215. (doi: 10.2353/ajpath.2010.100220)

Elsberger, B., Fullerton, R., Zino, S., Jordan, F., Mitchell, T.J., Brunton, V.G., Mallon, E.A., Shiels, P.G. and Edwards, J. (2010) Breast cancer patients' clinical outcome measures are associated with Src kinase family member expression. British Journal of Cancer, 103(6), pp. 899-909. (doi: 10.1038/sj.bjc.6605829)

Edwards, J. , Tannahill, C., Obondo, C., Elsberger, B., Mallon, E., Wilson, C. and Doughty, J. (2010) Expression and activation of Akt and NFkB in breast cancer patients. European Journal of Cancer Supplements, 8(6), pp. 5-6. (doi: 10.1016/j.ejcsup.2010.06.015)

Nam, N.A., Ahmad, I., Edwards, J. , Leung, H.Y. and White, R.J. (2010) RNA polymerase III transcription deregulation in cancer: study of Brf1 expression in prostate cancer. European Journal of Cancer Supplements, 8(5), p. 138. (doi: 10.1016/S1359-6349(10)71344-6)

Tan, S., Ahmad, I., Singh, L., Nixon, C., Edwards, J. and Leung, H. (2010) Grp78 activity is associated with androgen receptor status and upregulated in Hormone-Refractory prostate cancer. European Journal of Cancer Supplements, 8(5), p. 44. (doi: 10.1016/S1359-6349(10)70975-7)

Edwards, J. (2010) Src kinase inhibitors: an emerging therapeutic treatment option for prostate cancer. Expert Opinion on Investigational Drugs, 19(5), pp. 605-614. (doi: 10.1517/13543781003789388)

Kirkegaard, T., Witton, C.J., Edwards, J., Nielsen, K.V., Jensen, L.B., Campbell, F.M., Cooke, T.G. and Bartlett, J.M.S. (2010) Molecular alterations in AKT1, AKT2 and AKT3 detected in breast and prostatic cancer by FISH. Histopathology, 56(2), pp. 203-211. (doi: 10.1111/j.1365-2559.2009.03467.x)

Baneshi, M. R., Warner, P., Anderson, N., Edwards, J. , Cooke, T. G. and Bartlett, J. M. S. (2010) Tamoxifen resistance in early breast cancer: statistical modelling of tissue markers to improve risk prediction. British Journal of Cancer, 102(10), pp. 1503-1510. (doi: 10.1038/sj.bjc.6605627)

Darrien, J., Edwards, J. , McMillan, D. and Horgan, P. (2010) The inter-relationships between tumoural inflammatory infiltrate and expression of C-reactive protein, HIF-1 and NFKb in patients undergoing synchronous colorectal and hepatic resection for Dukes' D colorectal cancer. British Journal of Surgery, 97(S2), p. 65. (doi: 10.1002/bjs.7050)

Elsberger, B., Stewart, B., Tatarov, O. and Edwards, J. (2010) Is Src a Viable Target for Treating Solid Tumours? Current Cancer Drug Targets, 10(7), pp. 683-694. (doi: 10.2174/156800910793605802)

Elsberger, B., Tan, B.A., Mallon, E.A., Brunton, V.G. and Edwards, J. (2010) Is there an association with phosphorylation and dephosphorylation of Src kinase at tyrosine 530 and breast cancer patient disease-specific survival. British Journal of Cancer, 103(12), pp. 1831-1834. (doi: 10.1038/sj.bjc.6605913)

Long, J. S., Edwards, J. , Watson, C., Tovey, S., Mair, K. M., Schiff, R., Natarajan, V., Pyne, N. J. and Pyne, S. (2010) Sphingosine Kinase 1 Induces Tolerance to Human Epidermal Growth Factor Receptor 2 and Prevents Formation of a Migratory Phenotype in Response to Sphingosine 1-Phosphate in Estrogen Receptor-Positive Breast Cancer Cells. Molecular and Cellular Biology, 30(15), pp. 3827-3841. (doi: 10.1128/MCB.01133-09)

Long, J. S., Fujiwara, Y., Edwards, J. , Tannahill, C.L., Tigyi, G., Pyne, S. and Pyne, N. J. (2010) Sphingosine 1-Phosphate Receptor 4 Uses HER2 (ERBB2) to Regulate Extracellular Signal Regulated Kinase-1/2 in MDA-MB-453 Breast Cancer Cells. Journal of Biological Chemistry, 285(46), pp. 35957-35966. (doi: 10.1074/jbc.M110.117945)

2009

Elsberger, B., Tan, B., Brown, S., Mitchell, T., Mallon, E., Tovey, S., Brunton, V., Cooke, T. and Edwards, J. (2009) Is Expression or Activation of Src Kinase Associated with Cancer-Specific Survival in ER-, PR- and HER2-Negative Breast Cancer Patients? American Journal of Pathology, 175(4), pp. 1389-1397. (doi: 10.2353/ajpath.2009.090273)

Elsberger, B., Fullerton, R., Tan, A.B. and Edwards, J. (2009) Survival analysis of most expressed src kinase family members (SKFMs) in human breast carcinoma. Virchows Archiv, 455(Sup. 1), p. 75. (doi: 10.1007/s00428-009-0805-z)

Elsberger, B., Zino, S., Jordan, F., Shiels, P. and Edwards, J. (2009) Are Src kinase family members (SKFMS) expressed in human breast cancer? Virchows Archiv, 455(Sup. 1), p. 33. (doi: 10.1007/s00428-009-0805-z)

Stewart, B., Mitchell, T., Leung, H.Y., Robson, C.N. and Edwards, J. (2009) Membrane c-Src kinase expression is associated with decreased prostate cancer specific survival. BJU International, 103, p. 21.

Guo, Z. et al. (2009) A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Research, 69(6), pp. 2305-2313. (doi: 10.1158/0008-5472.CAN-08-3795)

McGlynn, L.M., Kirkegaard, T., Edwards, J., Tovey, S., Cameron, D., Twelves, C., Bartlett, J.M.S. and Cooke, T.G. (2009) Ras/Raf-1/MAPK pathway mediates response to tamoxifen but not chemotherapy in breast cancer patients. Clinical Cancer Research, 15(4), pp. 1487-1495. (doi: 10.1158/1078-0432.CCR-07-4967)

Brown, S., Mallon, E., Edwards, J. , McGlynn, L., Campbell, F. and Timothy, C. (2009) Is the biology of breast cancer changing? A study of hormone receptor status and grade of breast cancers 1984-1986 and 1996-97. Cancer Research, 69(2), S228. (doi: 10.1158/0008-5472.SABCS-3088)

Brown, S.B.F., Mallon, E.A., Edwards, J., Campbell, F.M., McGlynn, L.M., Elsberger, B. and Cooke, T.G. (2009) Is the biology of breast cancer changing? A study of hormone receptor status 1984-1986 and 1996-1997. British Journal of Cancer, 100(5), pp. 807-810. (doi: 10.1038/sj.bjc.6604934)

Elsberger, B., Tovey, S., Tan, B., Brown, S., Brunton, V., Mallon, E., Cooke, T. and Edwards, J. (2009) Phosphorylated c-Src predicts clinical outcome in triple negative breast cancers. Cancer Research, 69(2), S179. (doi: 10.1158/0008-5472.SABCS-2076)

Elsberger, B., Tovey, S., Tan, B., Brown, S., Brunton, V., Mallon, E., Cooke, T. and Edwards, J. (2009) Role of Src family members in breast cancer-dependent on site of phosphorylation. Cancer Research, 69(2), S178-S179. (doi: 10.1158/0008-5472.SABCS-2074)

Elsberger, B., Zino, S., Fullerton, R., Mitchell, T.J., Shiels, P. and Edwards, J. (2009) Are expression levels of Src kinase family members in human breast tissue related to clinical outcome of breast cancer patients? European Journal of Cancer Supplements, 7(2), pp. 93-94. (doi: 10.1016/S1359-6349(09)70316-7)

Elsberger, B., Zino, S., Jordan, F., Fullerton, R., Mitchell, T., Shiels, P. and Edwards, J. (2009) Src kinase family members expression in human breast tissue and their association to clinical outcome of breast cancer patients. Cancer Research, 69(24 Sup), S866-S867. (doi: 10.1158/0008-5472.SABCS-09-6130)

McGlynn, L., Curle, J., Edwards, J. and Shiels, P. (2009) Evaluating the role of sirtuins 5, 6 & 7 in breast cancer. Cancer Research, 69(24 Sup), S657. (doi: 10.1158/0008-5472.SABCS-09-3034)

McGlynn, L., Reilly, J., Edwards, J. and Shiels, P. (2009) Role of SIRT2, SIRT3 and SIRT4 in breast cancer. Cancer Research, 69(24 Sup), S656-S657. (doi: 10.1158/0008-5472.SABCS-09-3032)

Tannahill, C., Obondo, C., Al-Murri, A., Doughty, J., Lannigan, A., Wilson, C., McMillan, D. and Edwards, J. (2009) The relationship between tumour NF-kB expression, hormone status, and clinicopathological factors in primary invasive breast cancer. Cancer Research, 69(2), S263. (doi: 10.1158/0008-5472.SABCS-4038)

Tannahill, C., Obondo, C., Tovey, S., Orange, C., Doughty, J., Wilson, C., Cooke, T., McMillan, D. and Edwards, J. (2009) The relationship between tumour NF-kB expression, hormone status and survival in primary invasive breast cancer. Cancer Research, 69(2), S264. (doi: 10.1158/0008-5472.SABCS-4041)

Tatarov, O., Mitchell, T.J., Seywright, M., Leung, H.Y. , Brunton, V.G. and Edwards, J. (2009) Src family kinase activity is up-regulated in hormone refractory prostate cancer. Clinical Cancer Research, 15(10), pp. 3540-3549. (doi: 10.1158/1078-0432.CCR-08-1857)

Tovey, S., Marla, S., Brown, S., Burton, P., Canney, P., Stallard, S., Mallon, E., Edwards, J. and Cooke, T. (2009) Poor survival outcomes in HER2 positive breast cancer patients with low grade, node negative tumours. Implications for trastuzumab therapy? Cancer Research, 69(2), S98-0. (doi: 10.1158/0008-5472.SABCS-702)

Tovey, S., Tan, B., Campbell, J., Elsberger, B., Brunton, V., Mallon, E., Cooke, T. and Edwards, J. (2009) Activated c-Src (Y215) kinase expression predicts for early relapse on tamoxifen in human breast cancer. Cancer Research, 69(2), S212-0. (doi: 10.1158/0008-5472.SABCS-3025)

Tovey, S.M., Brown, S.B., Doughty, J.C., Mallon, E.A., Cooke, T.G. and Edwards, J. (2009) Poor survival outcomes in HER2 positive breast cancer patients with low grade, node negative tumours. British Journal of Cancer, 100(5), pp. 680-683. (doi: 10.1038/sj.bjc.6604940)

Tovey, S.M., Edwards, J. , Brown, S., Mallon, E. and Doughty, J. (2009) Poor survival outcomes in elderly HER2 positive breast cancer patients. Cancer Research, 69(24 Sup), S595. (doi: 10.1158/0008-5472.SABCS-09-2010)

Watson, C., Kipgen, D., Orange, C., Tovey, S., Cooke, T., Edwards, J. and Leung, H. (2009) Role of extracellular signal-regulated kinase 5 (ERK5) in human breast cancer. Cancer Research, 69(2), S264. (doi: 10.1158/0008-5472.SABCS-4042)

2008

Tovey, S., Edwards, J. , Brown, S., Mallon, E. and Cooke, T. (2008) Poor survival outcomes in HER2 positive breast cancer patients with low grade, node negative tumours. European Journal of Cancer Supplements, 6(9), pp. 105-106. (doi: 10.1016/S1359-6349(08)71578-7)

Kirkegaard, T., Naresh, A., Sabine, V.S., Tovey, S.M., Edwards, J., Dunne, B., Cooke, T.G., Jones, F.E. and Bartlett, J.M.S. (2008) Expression of tumor necrosis factor [alpha] converting enzyme in endocrine cancers. American Journal of Clinical Pathology, 129, pp. 735-743. (doi: 10.1309/N6YB6YDVF58YCNHN)

Lamb, G.W., McArdle, P.A., Ramsey, S., McNichol, A.M., Edwards, J. , Aitchison, M. and McMillan, D.C. (2008) The relationship between the local and systemic inflammatory responses and survival in patients undergoing resection for localized renal cancer. BJU International, 102(6), pp. 756-761. (doi: 10.1111/j.1464-410X.2008.07666.x)

Campbell, E.J., McDuff, E., Tatarov, O., Tovey, S., Brunton, V.G., Cooke, T.G. and Edwards, J. (2008) Phosphorylated c-Src in the nucleus is associated with improved patient outcome in ER-positive breast cancer. British Journal of Cancer, 99(11), pp. 1769-1774. (doi: 10.1038/sj.bjc.6604768)

McCall, P., Gemmell, L.K., Mukherjee, R., Bartlett, J.M.S. and Edwards, J. (2008) Phosphorylation of the androgen receptor is associated with reduced survival in hormonerefractory prostate cancer patients. British Journal of Cancer, 98(6), pp. 1094-1101. (doi: 10.1038/sj.bjc.6604152)

McCall, P., Witton, C.J., Grimsley, S., Nielsen, K.V. and Edwards, J. (2008) Is PTEN loss associated with clinical outcome measures in human prostate cancer? British Journal of Cancer, 99(8), pp. 1296-1301. (doi: 10.1038/sj.bjc.6604680)

McCracken, S.R.C., Ramsay, A., Heer, R., Mathers, M.E., Jenkins, B.L., Edwards, J., Robson, C.N., Marquez, R., Cohen, P. and Leung, H.Y. (2008) Aberrant expression of extracellular signal-regulated kinase 5 in human prostate cancer. Oncogene, 27(21), pp. 2978-2988. (doi: 10.1038/sj.onc.1210963)

Traynor, P., McGlynn, L.M., Mukherjee, R., Grimsley, S.L.S., Bartlett, J.M.S. and Edwards, J. (2008) An increase in N-Ras expression is associated with development of hormone refractory prostate cancer in a subset of patients. Disease Markers, 24(3), pp. 157-165.

2007

Edwards, J. and Leung, H.Y. (2007) Editorial comment on: increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells. European Urology, 52(6), pp. 1680-1681. (doi: 10.1016/j.eururo.2007.01.098)

Tam, L., McGlynn, L.M., Traynor, P., Mukherjee, R., Bartlett, J.M.S. and Edwards, J. (2007) Expression levels of the JAK/STAT pathway in the transition from hormone-sensitive to hormone-refractory prostate cancer. British Journal of Cancer, 97(3), pp. 378-383. (doi: 10.1038/sj.bjc.6603871)

Teo, K., Gemmell, L., Mukherjee, R., Traynor, P. and Edwards, J. (2007) Bad expression influences time to androgen escape in prostate cancer. BJU International, 100(3), pp. 691-696. (doi: 10.1111/j.1464-410X.2007.07001.x)

2006

Edwards, J., Traynor, P., Munro, A., Pirrett, C.F., Dunne, B. and Bartlett, J.M.S. (2006) The role of HER1-HER4 and EGFRvIII in hormone-refractory prostate cancer. Clinical Cancer Research, 12(1), pp. 123-130. (doi: 10.1158/1078-0432.CCR-05-1445)

Kirkegaard, T., Edwards, J. , Tovey, S., McGlynn, L.M., Krishna, S.N., Mukherjee, R., Tam, L., Munro, A.F., Dunne, B. and Bartlett, J.M. (2006) Observer variation in immunohistochemical analysis of protein expression, time for a change? Histopathology, 48(7), pp. 787-794. (doi: 10.1111/j.1365-2559.2006.02412.x)

2005

Bartlett, J.M., Brawley, D., Grigor, K.M., Munro, A.F., Dunne, B. and Edwards, J. (2005) Type I receptor tyrosine kinases are associated with hormone escape in prostate cancer. Journal of Pathology, 205(4), pp. 522-529. (doi: 10.1002/path.1735)

Edwards, J. and Bartlett, J.M.S. (2005) The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 1: modifications to the androgen receptor. BJU International, 95(9), pp. 1320-1326. (doi: 10.1111/j.1464-410X.2005.05526.x)

Edwards, J. and Bartlett, J.M.S. (2005) The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 2: androgen-receptor cofactors and bypass pathways. BJU International, 95(9), pp. 1327-1335. (doi: 10.1111/j.1464-410X.2005.05527.x)

Mukherjee, R., Bartlett, J.M.S., Krishna, N.S., Underwood, M.A. and Edwards, J. (2005) Raf-1 expression may influence progression to androgen insensitive prostate cancer. Prostate, 64(1), pp. 101-107. (doi: 10.1002/pros.20211)

Mukherjee, R., Edwards, J., Underwood, M.A. and Bartlett, J.M.S. (2005) The relationship between angiogenesis and cyclooxygenase-2 expression in prostate cancer. BJU International, 96(1), pp. 62-66. (doi: 10.1111/j.1464-410X.2005.05568.x)

2004

Edwards, J. , Mukherjee, R., Munro, A.F., Wells, A.C., Almushatat, A. and Bartlett, J.M.S. (2004) HER2 and COX2 expression in human prostate cancer. European Journal of Cancer, 40(1), pp. 50-55. (doi: 10.1016/j.ejca.2003.08.010)

2003

Edwards, J. , Krishna, N.S., Grigor, K.M. and Bartlett, J.M.S. (2003) Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. British Journal of Cancer, 89(3), pp. 552-556. (doi: 10.1038/sj.bjc.6601127)

Edwards, J. , Krishnan, S., Witton, C.J. and Bartlett, J.M.S. (2003) Gene amplifications associated with the development of hormone- resistant prostate cancer. Clinical Cancer Research, 9(14), pp. 5271-5281.

2002

Edwards, J. , Duncan, P., Going, J.J., Watters, A.D., Grigor, K.M. and Bartlett, J.M.S. (2002) Identification of loci associated with putative recurrence genes in transitional cell carcinoma of the urinary bladder. Journal of Pathology, 196(4), pp. 380-385. (doi: 10.1002/path.1052)

Brown, R.S.D., Edwards, J. , Bartlett, J.M.S., Jones, C. and Dogan, A. (2002) Routine acid decalcification of bone marrow samples can preserve DNA for FISH and CGH studies in metastatic prostate cancer. Journal of Histochemistry and Cytochemistry, 50(1), pp. 113-115.

Brown, R.S.D., Edwards, J. , Dogan, A., Payne, H., Harland, S.J., Bartlett, J.M.S. and Masters, J.R.W. (2002) Amplification of the androgen receptor gene in bone metastases from hormone-refractory prostate cancer. Journal of Pathology, 198(2), pp. 237-244. (doi: 10.1002/path.1206)

Mir, K., Edwards, J. , Paterson, P.J. , Hehir, M., Underwood, M.A. and Bartlett, J.M.S. (2002) The CAG trinucleotide repeat length in the androgen receptor does not predict the early onset of prostate cancer. BJU International, 90(6), pp. 573-578. (doi: 10.1046/j.1464-410X.2002.02981.x)

2001

Edwards, J. , Duncan, P., Going, J.J., Grigor, K.M., Watters, A.D. and Bartlett, J.M.S. (2001) Loss of heterozygosity on chromosomes 11 and 17 are markers of recurrence in TCC of the bladder. British Journal of Cancer, 85(12), pp. 1894-1899. (doi: 10.1054/bjoc.2001.2159)

Edwards, J. , Krishna, N.S., Mukherjee, R., Watters, A.D., Underwood, M.A. and Bartlett, J.M.S. (2001) Amplification of the androgen receptor may not explain the development of androgen-independent prostate cancer. BJU International, 88(6), pp. 633-637. (doi: 10.1046/j.1464-410X.2001.02350.x)

1999

Edwards, J. and Bartlett, J.M.S. (1999) Induction of apoptosis and inhibition of cellular proliferation as a dual approach to treatment of ovarian cancer. International Journal of Oncology, 15(3), pp. 583-588.

This list was generated on Wed Nov 20 16:52:54 2024 GMT.

Jump to: Articles | Book Sections | Conference or Workshop Item

Number of items: 219.

Articles

Shamis, S. A.K. et al. (2024) Elucidation of dysregulated pathways associated with hypoxia in ER-negative breast cancer. Cancer Medicine, (Accepted for Publication)

Montes, M. et al. (2020) Determining the prognostic significance of IKKα in prostate cancer. Prostate, 80(14), pp. 1188-1202. (doi: 10.1002/pros.24045) (PMID:33258506)

Rooney, N. et al. (2020) RUNX1 is a driver of renal cell carcinoma correlating with clinical outcome. Cancer Research, 80(11), pp. 2325-2339. (doi: 10.1158/0008-5472.CAN-19-3870) (PMID:32156779)

Campbell, K. J. et al. (2018) MCL-1 is a prognostic indicator and drug target in breast cancer. Cell Death and Disease, 9, 19. (doi: 10.1038/s41419-017-0035-2) (PMID:29339815) (PMCID:PMC5833338)

Sierra Gonzalez, P. et al. (2018) Mannose impairs tumour growth and enhances chemotherapy. Nature, 563, pp. 719-723. (doi: 10.1038/s41586-018-0729-3) (PMID:30464341)

McGlynn, L.M. et al. (2014) SIRT2: Tumour suppressor or tumour promoter in operable breast cancer? European Journal of Cancer, 50(2), pp. 290-301. (doi: 10.1016/j.ejca.2013.10.005) (PMID:24183459)

Patel, R. et al. (2013) Sprouty2, PTEN, and PP2A interact to regulate prostate cancer progression. Journal of Clinical Investigation, 123(3), pp. 1157-1175. (doi: 10.1172/JCI63672)

Qayyum, T. et al. (2012) Expression and prognostic significance of Src family members in renal clear cell carcinoma. British Journal of Cancer, 107(5), pp. 856-863. (doi: 10.1038/bjc.2012.314)

Edwards, J. (2010) Src kinase inhibitors: an emerging therapeutic treatment option for prostate cancer. Expert Opinion on Investigational Drugs, 19(5), pp. 605-614. (doi: 10.1517/13543781003789388)

Elsberger, B., Stewart, B., Tatarov, O. and Edwards, J. (2010) Is Src a Viable Target for Treating Solid Tumours? Current Cancer Drug Targets, 10(7), pp. 683-694. (doi: 10.2174/156800910793605802)

McGlynn, L., Curle, J., Edwards, J. and Shiels, P. (2009) Evaluating the role of sirtuins 5, 6 & 7 in breast cancer. Cancer Research, 69(24 Sup), S657. (doi: 10.1158/0008-5472.SABCS-09-3034)

McGlynn, L., Reilly, J., Edwards, J. and Shiels, P. (2009) Role of SIRT2, SIRT3 and SIRT4 in breast cancer. Cancer Research, 69(24 Sup), S656-S657. (doi: 10.1158/0008-5472.SABCS-09-3032)

Book Sections

Conference or Workshop Item

This list was generated on Wed Nov 20 16:52:54 2024 GMT.

Grants

Grants and Awards listed are those received whilst working with the University of Glasgow.

Requirement for a new digital slide scanner within the Glasgow Tissue Research Facility
Beatson Cancer Charity
2024 - 2025
Investigating immunological prevention strategies for precursor lesions of colon cancer
Cancer Research UK
2024 - 2025
Single cell spatial transcriptomics to investigate colorectal adenoma immune contexture and its association with future polyp or cancer risk in bowel screening patients
Guts UK Charity
2024 - 2025
D04: Derivation of novel non-invasive radiomic and AI-based classifiers to determine molecular behaviour of rectal cancer and its treatment response to radiotherapy
Cancer Research UK
2024 - 2028
Molecular characterisation of colonic polyps to understand metachronous disease and CRC development
Beatson Cancer Charity
2023 - 2024
ECMC QQR 2023-2028
Cancer Research UK
2023 - 2024
Utilising AI for the Detection of Novel Biomarkers in Cancer
Beatson Cancer Charity
2023 - 2024
Integrated Technologies for Improved Polyp Surveillance (INCISE) V2.0
Innovate UK
2023 - 2025
IL6/JAK/STAT3 pathway in colorectal cancer
Office of the Chief Scientific Adviser
2023 - 2025
Development and validation of prognostic biomarkers for metastatic stratification in colorectal cancer patients.
Bowel Cancer UK
2023 - 2024
An investigation into the therapeutic potential of combining radiotherapy and IKK inhibition for rectal cancer patients
Office of the Chief Scientific Adviser
2023 - 2025
Development of a first-in-class preclinical IKKa inhibitor for the treatment of castrate-resistant prostate cancer
Prostate Cancer UK
2022 - 2022
CRUK Centre Renewal 2021
Cancer Research UK
2022 - 2023
Combining Radiation with JAK inhibitors as a novel therapeutic strategy
Cancer Research UK
2022 - 2022
Inhibition of STAT3 in combination with radiotherapy as a novel therapeutic approach for colorectal cancer
Wellcome Trust
2022 - 2022
TransSCOT - Scot Genomics
Beatson Institute for Cancer Research
2022 - 2023
McNab Funding - Disease Positioning Project
Beatson Institute for Cancer Research
2021 - 2022
Utilising spatial transcriptomics to investigate underlying mechanisms of aberrant STAT3 signalling in colorectal cancer
NHS Greater Glasgow and Clyde Endowment Funds
2021 - 2022
Integrating digital pathology and genomic analysis to optimise and streamline colonic surveillance within the Scottish Bowel Screening Programme (SBoSP) to enable early detection of Colorectal neoplasia.
Innovate UK
2020 - 2023
Investigation into the potential immune primimg effect of chemo/radiotherapy on the tumour in rectal cancer
NHS Greater Glasgow and Clyde Endowment Funds
2020 - 2021
Prognostic biomarkers in primary operable triple negative breast cancer
Royal College of Physicians and Surgeons of Glasgow
2019 - 2021
Translational Scot Trial
University of Oxford
2019 - 2021
Research donation to investigate inflammatory signalling pathways in breast cancer - E Morrow
NHS Greater Glasgow and Clyde
2018 - 2019
The development of a new pre-clinical model to identify predicative biomakers for Prostate Cancer
NHS Greater Glasgow and Clyde
2018 - 2018
Scottish Genomics Project Part time Research Doctor
NHS Greater Glasgow and Clyde Endowment Funds
2017 - 2018
The role of IKK-a and p45-IKK-a in colorectal cancer
NHS Greater Glasgow and Clyde Endowment Funds
2017 - 2018
Androgen receptor phosphorylation as a predictor of response to prostate cancer treatment, Dr Payne
NHS Greater Glasgow and Clyde Endowment Funds
2016 - 2017
Developing a quantitative fluorescent microscopy technique for androgen receptor assessment in prostate cancer
NHS Greater Glasgow and Clyde Endowment Funds
2016 - 2017
Identification of biomarkers to predict response to synergistic targeting of AR and PI3K pathway in castrate resistant prostate cancer.
Prostate Cancer UK
2015 - 2018
First-in-class Selective IKKalpha Inhibitors for the Treatment of Castrate Resistant Prostate Cancer (CRPC) and Pancreatic Cancer
Medical Research Council
2015 - 2017
Estabilishing prostate cancer patient derived cell lines and xenografts for use in validation of predictive biomarkers (Confidence in Concept)
Medical Research Council
2014 - 2015
CXCL 12 as an assay system for IKKalpha inhibitor drugs
Cancer Research UK
2014 - 2016
The relationship between genetic aberrations and CpG Island Methylator Phenotype in colorectal cancer
Cancer Research UK
2012 - 2013
The relationship between clinicopathological factors, microsatellite instability status and survival in patients with colorectal cancer.
Royal College of Physicians and Surgeons of Glasgow
2012 - 2013
The role of NF-kB and MMP-9 in predicting recurrence from Ulcerative Colitis following colectomy
Cunningham Trust
2012 - 2013
The role of IKKa and IKKb in prostate cancer progression
Prostate Cancer UK
2011 - 2014
The role of Src kinase family in Colorectal cancer.
Royal College of Surgeons of Edinburgh
2011 - 2012
The role of the androgen receptor in benign prostatic hyperplasia
Cunningham Trust
2011 - 2014
Use of cellular proliferation index as a novel method for improving clinical management of prosthetic enlargement
Cunningham Trust
2010 - 2011
A comprehensive multidisciplinary approach to target the inhibitory kappa B kinase pathway to discover novel therapies in prostate cancer
Cancer Research UK
2010 - 2014
Testing the potential of PAR-2 as a therapeutic target in prostate cancer
Cancer Research UK
2010 - 2012
The role of Src kinase family members & downstream pathway effectors in the development & progression of prostate cancer.
NHS Greater Glasgow and Clyde Endowment Funds
2009 - 2011
Src Kinase and downstream pathway effectors in prostate cancer
Royal College of Physicians & Surgeons of Glasgow
2009 - 2010
Is phosphorylation of the androgen receptor of clinical significance in the development and progression of prostrate cancer?
Association for International Cancer Research
2008 - 2010
The role of the Src kinase family in breast cancer.
Royal College of Surgeons of Edinburgh
2007 - 2011
Validation of the MEK5/ERK5 pathway as targets for therapy in prostate cancer
Prostate Cancer Charity
2007 - 2010
The role of NF-kB expression and interaction with the inflammatory response to breast cancer.
Western Infirmary
2007 - 2010
Prostate cancer research project
Cruden Foundation Limited
2006 - 2009
The role of Src family kinases in the development of androgen independent prostate cancer
Cancer Research UK
2006 - 2007
The role of the P13K/Akt pathway in the development of hormone refractory prostate cancer
Association for International Cancer Research
2005 - 2007
What are the molecular mechanisms responsible for development/progression of prostate cancer?
Royal College of Physicians & Surgeons of Glasgow
2005 - 2007
Is the P13K/Akt pathway involved in the development of hormone refactory prostate cancer?
NHS Trust Prostate Cancer Fund
2005 - 2005
Signal Transduction in Cancer
The Royal Society
2005 - 2005
Is the P13K/Akt pathway involved in the development of hormone refactory prostate cancer?
Prostate Cancer Charitable Trust
2004 - 2005
What are the roles of the P13K/Akt and RAS/RAF/MAP kinase pathways in the development of hormone refractory prostate cancer
Tenovus Scotland
2002 - 2005

Supervision

Al Badran, Sara Samir Foad
Examining the colonic polyp microbiome and its association with future colorectal neoplasia risk in a bowel screening population

Since 2007, Joanne has supervised 23 PhD students, 8 MD students, 26 RA posts and 8 technical posts.